Levetiracetam Solution
Product Images NDC 70518-3804

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-3804). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of a medication called levETIRAcetam, available in the form of an oral solution. Each cup contains 10 mL of the solution with a strength of 1000mg. The medication is repackaged by RemedyRepack Inc. The lot number and expiration date are not available. The manufacturer is Aurohindo located in Nagar, India. The National Drug Code (NDC) for this product is 70518-3804-00, and the source NDC is 65862-0250-47. The medication should be stored between 20-25°C (68-77°F) with excursions permitted between 15-30°C (59-86°F) according to the United States Pharmacopeia (USP) guidelines. The text also advises keeping this medication, as well as all medications, out of the reach of children. For detailed usage instructions, refer to the package insert.*
FDA Label Image

Mm2 (Levetiracetam 1000mg 10ml 70518 3804 01)

Mm2 (Levetiracetam 1000mg 10ml 70518 3804 01)
Not available*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
FDA Label Image

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
This text provides a graph depicting the responder rate (250% reduction from baseline) in PGTC seizure frequency per week in Study 7. The graph shows the percentage of patients on placebo (N<4) and levetiracetam (N:79) who achieved a reduction in seizure frequency. It indicates a statistically significant difference between the two groups. The graph also includes percentages at various intervals, such as 100%, 90%, 80%, 72.2%, 60%, 50%, 45.2%, 30%, 20%, and 10%.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.